ArticleInvestigative ophthalmology & visual science2025
Maresin 1 Ameliorates Blue Light Overexposure-Induced Meibomian Gland Dysfunction via Inhibition of NLRP3/Caspase-1/GSDMD-Mediated Pyroptosis.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Blue light emitted from digital screens represents a significant environmental factor contributing to computer vision syndrome-related ocular surface damage. This study aimed to investigate the protective effects of maresin 1 (MaR1), a specialized proresolving lipid mediator derived from docosahexaenoic acid, in meibomian gland dysfunction (MGD) induced by blue light overexposure in both in vivo and in vitro experiments. Methods: In vivo, male Sprague-Dawley rats were exposed to blue light for 1 month to induce MGD. After 14 days of MaR1 or PBS eye drop treatment, corneal fluorescein staining and inflammatory cytokine expression were evaluated. Lipid secretion and ductal keratinization were assessed using Nile red and keratin 1 staining. In vitro, pyroptosis was induced in primary rat meibomian gland epithelial cells (PRMGECs) by lipopolysaccharide and ATP stimulation, and pyroptosis-related protein expression was analyzed by immunofluorescence and Western blot analysis. Results: Excessive blue light exposure induced MGD-like clinical signs, characterized by extensive corneal fluorescein staining, obstruction of MG ducts, and a reduction in total glandular area in rats. Moreover, these ocular surface injuries were accompanied by the upregulation of IL-1β and IL-18 levels and the activation of NLRP3/caspase 1/GSDMD-mediated pyroptosis. Following MaR1 treatment, inflammatory cell infiltration was alleviated, the lipid secretion function of the meibomian glands was restored, and ductal hyperkeratinization was suppressed. In vitro, MaR1 significantly inhibited pyroptosis-related protein expression in the PRMGEC pyroptosis model. Conclusions: Our study indicated that MaR1 alleviated blue light-induced MGD by inhibiting NLRP3/caspase 1/GSDMD-mediated pyroptosis. This finding provides a novel therapeutic perspective for the treatment of environment-related dry eye disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.